Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drug
Upadacitinib Highlights: EULAR 2022
Efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis: a double-blind, randomized, placebo-controlled Phase III trial (Abstract # OP0016)
Abbvie's upadacitinib beat placebo in terms of signs and symptoms, pain, function, disease activity, and MRI-detected spine inflammation at Week 14 of the Phase III SELECT-AXIS 2 clinical trial.
According to the data, upadacitinib significantly enhanced the number of nr-axSpA patients who met the primary endpoint (45 percent) of ASAS40 at Week 14 as compared to placebo (23 percent ). Secondary endpoints included the Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Functional Index (BASFI), and MRI Spondyloarthritis Research Consortium of Canada (SPARCC) score for sacroiliac joints, and Ankylosing Spondylitis Quality of Life (ASQoL), as well as low disease activity. During 14 weeks of JAK inhibitor treatment, 48 percent and 46% of patients in the upadacitinib and placebo groups, respectively, had adverse events, with no fatalities or significant adverse cardiovascular events.
KOL Insights
This is the first study to show that the JAK inhibitor upadacitinib could be a therapeutic option in patients with active non-radiographic spondyloarthritis. The findings suggest that upadacitinib, an oral therapy, has the potential to help patients with nr-axSpA take control of their disease by reducing inflammation, relieving pain, and improving function.
Conclusion
The disease activity of 30% of people with SpA cannot be controlled with currently approved drugs, according to the current spondyloarthritis treatment regimen.
JAK inhibitors are the most recent class of synthetic (nonbiologic) disease-modifying antirheumatic medicines (DMARDs) that have been shown to be effective in clinical trials for the treatment of axSpA, and their oral route of administration makes them a more convenient treatment option than other therapies, potentially leading to higher compliance. Rheumatoid arthritis and psoriatic arthritis are two conditions for which the medication is already licensed.
Furthermore, Abbvie has previously demonstrated its leadership in the axSpA market with the approval of its lead candidate Rinvoq (upadacitinib) for the treatment of active ankylosing spondylitis. After 14 weeks of treatment, upadacitinib 15 mg once daily showed significant improvements in the signs and symptoms of nr-axSpA compared to placebo, indicating for the first time the possible use of upadacitinib as a treatment option in patients with nr-axSpA.
For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022
Some of the Latest Abstracts launched in EULAR 2022:
Diagnostic Imaging Equipment Market
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises North America, Europe, APAC, and RoW.
Sialidosis Market
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pain Management Devices Market
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.
To know more about our Competitive Services, Click here: Pharma Competitive Intelligence
https://www.delveinsight.com/consulting/competitive-intelligence-services
Also, take a glance at the Blogs by DelveInsight:
Comments
Post a Comment